Telaprevir and/or Boceprevir ought to be approved in China by the end of 2012; thus, by the 2021 date we’ve been discussing in this thread, these drugs will have had nine years to reduce the addressable patient pool with chronic HCV infection.
In short, I would say the big business opportunity for HCV drugs—Asia included—will come during the next 10 years, not in the decades thereafter.
20 years from now, HBV/HCV might not be a big issue in China
The U.S. government should lead by example and effectively screen it's population for Hep C. Perhaps afterword we would see such efficiencies in China. But don't count on it.
Market Data 
Markets 
AI
